TY - JOUR
T1 - Tocilizumab effectiveness in paediatric non-infectious uveitis
T2 - data from the International AIDA Network Registries on ocular inflammatory disorders
AU - Sota, Jurgen
AU - Breda, Luciana
AU - Paroli, Maria Pia
AU - Hashad, Soad
AU - de-La-Torre, Alejandra
AU - Guerriero, Silvana
AU - Tufan, Abdurrahman
AU - Cardona-López, Juanita
AU - Altamar-García, María José
AU - La Bella, Saverio
AU - Vitale, Antonio
AU - Biancalana, Edoardo
AU - Del Giudice, Emanuela
AU - Minoia, Francesca
AU - Al-Mayouf, Sulaiman
AU - Frediani, Bruno
AU - Cantarini, Luca
AU - Fabiani, Claudia
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.
PY - 2025
Y1 - 2025
N2 - To describe tocilizumab (TCZ) effectiveness in 15 children with refractory non-infectious uveitis. Reported outcomes are the number of relapses before and after treatment, steroid-sparing effect and drug retention rate. Macular oedema, fluorangiographic findings and ocular complications are also reported. The mean number of ocular relapses significantly decreased from 314 per 100 eyes/year to 106 per 100 eyes/year (p=0.016). A significant steroid-sparing effect was detected (p=0.037). TCZ drug survival was 77.4% at 6 months, followed by 61.9% at 12, 24 and 36 months of follow-up. Macular oedema and retinal vasculitis resolved in all affected eyes.
AB - To describe tocilizumab (TCZ) effectiveness in 15 children with refractory non-infectious uveitis. Reported outcomes are the number of relapses before and after treatment, steroid-sparing effect and drug retention rate. Macular oedema, fluorangiographic findings and ocular complications are also reported. The mean number of ocular relapses significantly decreased from 314 per 100 eyes/year to 106 per 100 eyes/year (p=0.016). A significant steroid-sparing effect was detected (p=0.037). TCZ drug survival was 77.4% at 6 months, followed by 61.9% at 12, 24 and 36 months of follow-up. Macular oedema and retinal vasculitis resolved in all affected eyes.
UR - https://www.scopus.com/pages/publications/105006548868
UR - https://www.scopus.com/pages/publications/105006548868#tab=citedBy
U2 - 10.1136/bjo-2025-327410
DO - 10.1136/bjo-2025-327410
M3 - Research Article
AN - SCOPUS:105006548868
SN - 0007-1161
JO - British Journal of Ophthalmology
JF - British Journal of Ophthalmology
ER -